Your browser doesn't support javascript.
loading
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
Masago, Katsuhiro; Fujita, Shiro; Muraki, Miho; Hata, Akito; Okuda, Chiyuki; Otsuka, Kyoko; Kaji, Reiko; Takeshita, Jumpei; Kato, Ryoji; Katakami, Nobuyuki; Hirata, Yukio.
Afiliação
  • Masago K; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. masago@fbri.org.
  • Fujita S; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. sfujita@fbri.org.
  • Muraki M; Thermo Fisher Scientific, Tokyo, Japan. miho.muraki@thermofisher.com.
  • Hata A; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. a-hata@fbri.org.
  • Okuda C; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. chiyuki-okuda@fbri.org.
  • Otsuka K; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. kyokoniceday@hotmail.co.jp.
  • Kaji R; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. naya@fbri.org.
  • Takeshita J; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. jumpeinr2tfm3@fbri.org.
  • Kato R; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. katou@fbri.org.
  • Katakami N; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. katakami@fbri.org.
  • Hirata Y; Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Cyuo-ku, Kobe City, Hyogo, 650-0047, Japan. yhirata@fbri.org.
BMC Cancer ; 15: 908, 2015 Nov 16.
Article em En | MEDLINE | ID: mdl-26572169
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Receptores ErbB / Neoplasias Pulmonares / Mutação / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Receptores ErbB / Neoplasias Pulmonares / Mutação / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article